scholarly journals Achieving Complete Radiological and Bio-Chemical Response as a Predictor of Long-Term Survival in Stage IV Epithelial Ovarian Cancer

Cureus ◽  
2021 ◽  
Author(s):  
Hafiz Abubakar Sarwar ◽  
Jhanzeb Iftikhar ◽  
Musa Azhar ◽  
Kiran Munawar ◽  
Muhammad Rashid Hanif ◽  
...  
2020 ◽  
Vol 1 (1) ◽  
pp. 15-18
Author(s):  
Hafiz Abubakar Sarwar ◽  
Jhanzeb Iftikhar ◽  
Samia Yasmeen ◽  
Fareeha Sheikh ◽  
Fatima Ali ◽  
...  

Objective: Our aim was to identify factors favoring long term survival in patients presenting with stage IV epithelial ovarian cancer.Methods: We did retrospective analysis of thirty patients with stage IV epithelial ovarian cancer diagnosed and treated at Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan from 2006 to 2013. Patient’s demographics, clinical data and histopathology were abstracted from cancer registry department of our hospital. Chi-square test was used to find the association between clinic-pathological variables and long term survival. Result: All patients received chemotherapy and surgery as per ovarian cancer guidelines. Of the thirty patients, eleven patients survived greater than four years median survival was recorded as thirty five months. Absence of co-morbidities and good performance status indicated good results of therapy however did not have statistically significant impact on survival. Higher CA-125 at presentation i.e.>1000(normal range : <21 U/ml), response to initial chemotherapy, interval cytoreductive surgery and complete response after induction therapy were significantly associated with long term survival (P<0.05).Conclusion: Prognosis of patients presenting with stage IV epithelial ovarian cancer remains poor. Very high values of CA-125 (>1000) at presentation, response to initial chemotherapy, interval surgical resection and complete remission after induction therapy, appear to be significant prognostic factors for long term survival. Further studies exploring molecular profiling and immunological factors are warranted.


2020 ◽  
Vol 5 (1) ◽  
pp. 15-18
Author(s):  
Hafiz Abubakar Sarwar ◽  
Jhanzeb Iftikhar ◽  
Samia Yasmeen ◽  
Fareeha Sheikh ◽  
Fatima Ali ◽  
...  

Objective: Our aim was to identify factors favoring long term survival in patients presenting with stage IV epithelial ovarian cancer.Methods: We did retrospective analysis of thirty patients with stage IV epithelial ovarian cancer diagnosed and treated at Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan from 2006 to 2013. Patient’s demographics, clinical data and histopathology were abstracted from cancer registry department of our hospital. Chi-square test was used to find the association between clinic-pathological variables and long term survival. Result: All patients received chemotherapy and surgery as per ovarian cancer guidelines. Of the thirty patients, eleven patients survived greater than four years median survival was recorded as thirty five months. Absence of co-morbidities and good performance status indicated good results of therapy however did not have statistically significant impact on survival. Higher CA-125 at presentation i.e.>1000(normal range : <21 U/ml), response to initial chemotherapy, interval cytoreductive surgery and complete response after induction therapy were significantly associated with long term survival (P<0.05).Conclusion: Prognosis of patients presenting with stage IV epithelial ovarian cancer remains poor. Very high values of CA-125 (>1000) at presentation, response to initial chemotherapy, interval surgical resection and complete remission after induction therapy, appear to be significant prognostic factors for long term survival. Further studies exploring molecular profiling and immunological factors are warranted.


2017 ◽  
Vol 116 (7) ◽  
pp. 964-971 ◽  
Author(s):  
Shana J Kim ◽  
Barry Rosen ◽  
Isabel Fan ◽  
Anna Ivanova ◽  
John R McLaughlin ◽  
...  

2020 ◽  
Vol 24 (3) ◽  
pp. 163-171
Author(s):  
Katarzyna Lepinay ◽  
Sebastian Szubert ◽  
Agnieszka Lewandowska ◽  
Tomasz Rajs ◽  
Krzysztof Koper ◽  
...  

2009 ◽  
Vol 5 (1) ◽  
pp. 44-50 ◽  
Author(s):  
Leniaud Louis ◽  
Sifer Christophe ◽  
Amy Cooper ◽  
David Nelson ◽  
Stacy Doran ◽  
...  

2007 ◽  
Vol 17 (5) ◽  
pp. 986-992 ◽  
Author(s):  
M. O. Nicoletto ◽  
S. Tumolo ◽  
R. Sorio ◽  
G. Cima ◽  
L. Endrizzi ◽  
...  

The purpose of this study was to compare long-term survival in first-line chemotherapy with and without platinum in advanced-stage ovarian cancer. From July 1987 to November 1992, 161 untreated patients with FIGO stage III–IV epithelial ovarian cancer were randomized: 81 patients received no platinum and 80 received platinum combination. Residual disease after surgery was <2 cm in 61 patients without platinum, 59 with platinum. Median age was 58 years in nonplatinum arm and 55 years in platinum arm (range: 15–73). Complete and partial responses were 51% and 10% for nonplatinum arm and 51% and 8% for platinum arm, respectively (P= 0.7960). Stable disease was observed in 18% of patients in nonplatinum arm and 15% of patients in platinum arm and progression in 20% of nonplatinum- and 21% of platinum-treated cases. Ten-year disease-free survival was 37% for therapy without platinum and 31% for platinum combination (P= 0.5679); 10-year overall survival was 23% without platinum and 31% with platinum combination (P= 0.2545). Fifteen-year overall survival showed a trend of short duration in favor of platinum (P= 0.0678). Relapses occurred after 60 months in ten patients (seven with and three without platinum). The overall and disease-free survivals at 5, 10, and 15 years show no statistically significant long-term advantage from the addition of cisplatin; however, there is a slight trend in its favor.


2016 ◽  
Author(s):  
Joanne Kotsopoulos ◽  
Isabel Fan ◽  
John McLaughlin ◽  
Barry Rosen ◽  
Taymaa May ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document